Amivantamab
CAS 1835520-85-8 1 FDA-DMF supplierBiologic
Overview
Amivantamab is a monoclonal antibody designed to target EGFR and MET receptors, used in the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations. It works by inhibiting tumor growth and promoting immune cell-mediated cytotoxicity.
Therapeutic areas
Oncology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.